Catapult Technology

Catapult Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments, specifically targeting hematological malignancies. The company's lead candidate, CAP-100, is a first-in-class humanized monoclonal antibody that targets the chemokine receptor CCR7, which is overexpressed in various leukemias and lymphomas. By blocking CCR7, CAP-100 aims to interrupt the migration of tumor cells to the protective microenvironment of the lymph nodes while simultaneously inducing potent cell killing through antibody-dependent cellular cytotoxicity (ADCC). Founded in 2015 as a joint venture between Spanish and Dutch partners, the company is currently advancing its lead program through Phase 1 clinical trials in patients with relapsed or refractory chronic lymphocytic leukemia.